Clinical trial NCT02360644: Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
Official title: Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Diseases
Deficiency, Vitamin D
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: University of Pittsburgh
name: National Institute of General Medical Sciences (NIGMS)
First posted: 2015-02-10
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study investigates the effect of vitamin D deficiency on drug metabolism and transport in patients with chronic kidney disease (CKD) and in healthy controls.

The central hypothesis is that vitamin D concentrations independently affect metabolism and transport function in CKD patients. An over-arching goal of this proposal is to make drug therapies safer and more effective to reduce the significant morbidity and mortality in patients with CKD.

Detailed description: Specific Aim 1: Determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will mechanistically evaluate the function of major pathways of metabolism and transport by prospectively studying clearance phenotypes utilizing "probe" drugs commonly used for this purpose in CKD patients and healthy volunteers under vitamin D deficient and replete states. Bupropion, midazolam, olmesartan, fexofenadine, in addition to an endogenous probe (N-methylnicotinamide), will be used to phenotype major phase I drug metabolizing enzymes \[cytochrome P450 2B6 (CYP2B6), cytochrome P450 3A4/5 (CYP3A4/5)\], and transporters \[multidrug resistance associated protein 2 (MRP2), P-glycoprotein (P-gp), and multidrug and toxin extrusion protein 1/2K (MATE1/2K)\], respectively. Hypothesis: The in vivo function of individual pathways of xenobiotic metabolism and transport are affected by vitamin D status (and CKD).

Specific Aim 2: Determine the effect of CKD on the in vivo function of individual CYPs responsible for vitamin D metabolism and the pharmacokinetics of cholecalciferol (vitamin D3). The research will prospectively measure the activity of CYP450s responsible for cholecalciferol metabolism, and simultaneously evaluate the pharmacokinetics (PK) of cholecalciferol after single- and multiple-dose administration to CKD patients (stages 1-5) and healthy volunteers. Hypothesis: CKD alters the activity of individual CYPs responsible for vitamin D metabolism, leading to modified clearance of cholecalciferol.

Eligibility criteria: Inclusion criteria for CKD patients:

* vitamin D deficient (\<30 ng/mL)
* hemoglobin \>10 g/dL
* willing to abstain from fruit juices or alcohol within 7 days of PK assessments
* no changes in prescription or nonprescription medications within 4 wks of study start
* age 18-70 yrs
* If a diagnosis of CKD, must be due to diabetes mellitus or hypertension
* Signed informed consent

Inclusion Criteria for Healthy Controls:

* vitamin D deficient (\<30 ng/mL)
* hemoglobin \>10 g/dL
* willing to abstain from fruit juices or alcohol within 7 days of PK assessments
* no changes in prescription or nonprescription medications within 4 wks of study start
* age 18-70 yrs
* Signed informed consent

Exclusion criteria for CKD patients:

* History of \>14 alcoholic drinks/wk
* Not likely to be compliant with study visits
* Pregnant or lactating
* Predisposition to or history of hypercalcemia
* History of allergy, sensitivity, or contraindication to probe drugs (seizures, drug metabolism interactions, etc)
* Use of prescribed or nonprescribed therapies that could interact with probe drugs (including prototypical inhibitors or inducers)
* Active autoimmune disease or active/recent infections requiring antimicrobial treatment within the previous 4 wks will be excluded to minimize inflammatory-mediated changes in vitamin D status and patient heterogeneity.
* Presence of clinically significant hepatic insufficiency (total bilirubin greater than 1.5 times the upper limit of normal or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range or liver disease
* Active seizure disorder or those patients receiving large doses of medications that are known to reduce seizure threshold
* Currently receiving cholecalciferol or a vitamin D analogue

Exclusion Criteria for Healthy Controls:

* History of \>14 alcoholic drinks/wk
* Not likely to be compliant with study visits
* Pregnant or lactating
* Predisposition to or history of hypercalcemia
* History of allergy, sensitivity, or contraindication to probe drugs (seizures, drug metabolism interactions, etc)
* Use of prescribed or nonprescribed therapies that could interact with probe drugs (including prototypical inhibitors or inducers)
* Active autoimmune disease or active/recent infections requiring antimicrobial treatment within the previous 4 wks will be excluded to minimize inflammatory-mediated changes in vitamin D status and patient heterogeneity.
* Presence of clinically significant hepatic insufficiency (total bilirubin greater than 1.5 times the upper limit of normal or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range or liver disease
* Active seizure disorder or those patients receiving large doses of medications that are known to reduce seizure threshold
* Currently receiving cholecalciferol or a vitamin D analogue
* Any clinical evidence of chronic kidney disease as defined by the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF DOQI) guidelines

Primary outcomes:
measure: Change in area under the plasma concentration time curves for probe drugs (bupropion, midazolam, olmesartan and fexofenadine) from baseline to 12 weeks.
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in area under the plasma concentration time curves for cholecalciferol from baseline to 12 weeks.
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Colorado, Denver
name: Melanie Joy, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References: